港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

1,772.232

+40.7992.36%

涨家数：7

跌家数：- -

平家数：1

市盈率：- -

高：1,805.863

开：1,735.522

低：1,735.522

收：1,731.433

数据加载中...

总览新闻资讯

维亚生物盘中异动早盘快速上涨5.26%报1.400港元

港股异动 | 宜明昂科-B(01541)盘中涨超6% 获国家药监局批准进行替达派西普联合珀维拉芙普α的肿瘤临床试验

A股CRO概念股发力上涨，博腾股份涨逾5%，药明康德涨逾4%，诺思格、阳光诺和、凯莱英涨逾3%。

康龙化成盘中异动快速上涨5.06%

泰格医药盘中异动快速拉升5.01%

药明康德盘中异动股价大涨3.07%报62.100港元

昭衍新药盘中异动股价大涨5.29%

宜明昂科(01541.HK)治疗肿瘤药物获内地批准进行临床试验

阿斯达克财经

基石药业：在澳大利亚递交CS5001联合标准治疗用于一线DLBCL的临床试验申请

【中信建投：AI制药潜力释放，有望重塑医药未来图景】中信建投研报表示，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。目前AI算法在临床前药物发现阶段已经有着深入且深刻的应用，海外头部临床CRO公司在临床试验中已经布局AI多年，完全由AI研发的新药有望在1-2年内成功上市。AI有望重塑药物发现的模式，并且为制药行业带来潜移默化且持续地降本增效，驱动AI制药管线和市场的快速增长，看好AI制药行业长期的发展潜力及前景。

中信建投：AI制药潜力释放，有望重塑医药未来图景

【基石药业-B(02616.HK)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请】基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。

基石药业-B(02616)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请

【宜明昂科-B(01541.HK)获国家药监局批准进行替达派西普联合珀维拉芙普α另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验】宜明昂科-B(01541.HK)发布公告，集团已获中华人民共和国国家药品监督管理局(国家药监局)批准进行IMM01(替达派西普)联合IMM2510(珀维拉芙普α)，另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验。这一重大进展标志着公司在快速推进IMM01(替达派西普)及IMM2510(珀维拉芙普α)的临床研究方面又迈出了关键一步。

宜明昂科-B(01541)获国家药监局批准进行替达派西普联合珀维拉芙普α另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验

第一三共/阿斯利康(AZN.US)重磅抗体偶联药物(ADC)Enhertu在3期临床试验中获得积极结果

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1576/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":1772.232,"timestamp":1741248510306,"preClose":1731.4331,"halted":0,"volume":100037287,"delay":0,"changeRate":0.023564,"change":40.79895,"pbRate":2.569388,"amount":2232823119,"amplitude":0.040626,"prevYearClose":1395.7731,"fiveDayClose":1794.354,"twentyDayClose":1587.977,"turnoverRate":0.00862,"marketCap":380565866496,"floatMarketCap":164754930944,"peRate":32.042796},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1805.8632,"amplitude":0.040626,"preClose":1731.4331,"low":1735.5215,"pbRate":"2.569388","latestPrice":1772.232,"volume":100037287,"delay":0,"open":1735.5215,"prevYearClose":1395.7731,"prevWeekClose":1699.456,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1794.354,"twentyDayClose":1587.977,"sixtyDayClose":1360.467,"secType":"PLATE","market":"HK","turnoverRate":0.00862,"peRate":32.042796,"marketCap":380565866496,"floatMarketCap":164754930944,"timestamp":1741248510306,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":7,"down":0,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517190854","title":"维亚生物盘中异动 早盘快速上涨5.26%报1.400港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517190854","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517190854?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 10:09","pubTimestamp":1741226951,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘10时09分，维亚生物股票出现异动，股价大幅拉升5.26%。截至发稿，该股报1.400港元/股，成交量157.2万股，换手率0.07%，振幅4.51%。资金方面，该股资金流入177.583万港元，流出25.9435万港元。维亚生物股票所在的生物技术行业中，整体涨幅为1.81%。其相关个股中，迈博药业-B、复宏汉霖、创胜集团-B涨幅较大，振幅较大的相关个股有迈博药业-B、复宏汉霖、创胜集团-B，振幅分别为30.30%、12.32%、11.80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306100911abea7ddd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306100911abea7ddd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01873","BK1576","BK1141"],"gpt_icon":0},{"id":"2517705069","title":"港股异动 | 宜明昂科-B(01541)盘中涨超6% 获国家药监局批准进行替达派西普联合珀维拉芙普α的肿瘤临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2517705069","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517705069?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 09:58","pubTimestamp":1741226284,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B盘中涨超6%，截至发稿，涨6.26%，报5.77港元，成交额1697.78万港元。消息面上，3月6日，宜明昂科-B发布公告，集团已获中华人民共和国国家药品监督管理局批准进行IMM01联合IMM2510，另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验。这一重大进展标志着公司在快速推进IMM01及IMM2510的临床研究方面又迈出了关键一步。凭借差异化的分子设计，IMM01表现出良好的安全性并证实其激活巨噬细胞的能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1583","BK1141","BK1576","BK1161","01541"],"gpt_icon":0},{"id":"2517779079","title":"A股CRO概念股发力上涨，博腾股份涨逾5%，药明康德涨逾4%，诺思格、阳光诺和、凯莱英涨逾3%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517779079","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517779079?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 09:50","pubTimestamp":1741225819,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1328615791.USD","LU2125910500.SGD","301333","BK0028","002821","BK1191","399300","LU0320764599.SGD","LU1046422090.SGD","LU2045819591.USD","LU2242644610.SGD","LU0456842615.SGD","BK1576","LU1997245094.SGD","BK0216","LU0708995583.HKD","LU2488822045.USD","BK0132","LU1997245177.USD","LU0052750758.USD","06821","BK1583","159982","BK1141","300363","02359","603259","688621","BK0239"],"gpt_icon":0},{"id":"2517970310","title":"康龙化成盘中异动 快速上涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517970310","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517970310?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 09:49","pubTimestamp":1741225742,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时49分，康龙化成股票出现异动，股价快速拉升5.06%。截至发稿，该股报16.600港元/股，成交量267.01万股，换手率0.91%，振幅3.42%。康龙化成股票所在的药品行业中，整体涨幅为0.30%。其相关个股中，德琪医药-B、兆科眼科-B、信达生物涨幅较大，振幅较大的相关个股有顺腾国际控股、德琪医药-B、兆科眼科-B，振幅分别为11.54%、8.16%、6.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094902abea7586&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094902abea7586&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03759","BK1141","BK1576"],"gpt_icon":0},{"id":"2517703249","title":"泰格医药盘中异动 快速拉升5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517703249","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517703249?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 09:48","pubTimestamp":1741225732,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时48分，泰格医药股票出现波动，股价急速拉升5.01%。截至发稿，该股报35.650港元/股，成交量90.1万股，换手率0.73%，振幅4.12%。机构评级方面，在所有15家参与评级的机构中，67%的券商给予买入建议，20%的券商给予持有建议，13%的券商给予卖出建议。泰格医药股票所在的生物技术行业中，整体涨幅为1.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094852963b7a8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094852963b7a8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1576","BK1141","BK1583"],"gpt_icon":0},{"id":"2517970331","title":"药明康德盘中异动 股价大涨3.07%报62.100港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517970331","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517970331?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 09:34","pubTimestamp":1741224865,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时34分，药明康德股票出现波动，股价大幅上涨3.07%。截至发稿，该股报62.100港元/股，成交量43.224万股，换手率0.11%，振幅1.83%。药明康德股票所在的生物技术行业中，整体涨幅为1.18%。截至招股书签署之日，药明康德通过药明康德新药仍间接持有汉邦科技8.05%的股份，是公司的第二大股东。2023年11月一审汉邦科技胜诉，Cytiva上诉后最高法已经受理，目前二审尚未判决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093426963b73e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093426963b73e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02359","BK1583","LU1046422090.SGD","LU0708995583.HKD","LU2242644610.SGD","LU0320764599.SGD","LU0052750758.USD","LU2045819591.USD","BK1576","LU2125910500.SGD","BK1141"],"gpt_icon":0},{"id":"2517340970","title":"昭衍新药盘中异动 股价大涨5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517340970","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517340970?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 09:31","pubTimestamp":1741224711,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时31分，昭衍新药股票出现异动，股价快速拉升5.29%。截至发稿，该股报14.720港元/股，成交量8.96万股，换手率0.08%，振幅5.15%。资金方面，该股资金流入108.566万港元，流出11.3696万港元。昭衍新药股票所在的生物技术行业中，整体涨幅为1.38%。其相关个股中，创胜集团-B、宜明昂科-B、药明巨诺-B涨幅较大，振幅较大的相关个股有百奥赛图-B、昭衍新药、康宁杰瑞制药-B，振幅分别为6.79%、5.15%、4.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093152963b72fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093152963b72fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","06127"],"gpt_icon":0},{"id":"2517630974","title":"宜明昂科(01541.HK)治疗肿瘤药物获内地批准进行临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2517630974","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517630974?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 09:06","pubTimestamp":1741223160,"startTime":"0","endTime":"0","summary":"宜明昂科(01541.HK) 公布，已获国家药监局批准进行IMM01 (替达派西普)联合IMM2510 (珀维拉芙普α)，另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230915102621607_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230915102621607_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1422537&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","03347","BK1576","BK1161","01541","BK1583"],"gpt_icon":0},{"id":"2517971231","title":"基石药业：在澳大利亚递交CS5001联合标准治疗用于一线DLBCL的临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2517971231","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517971231?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 08:29","pubTimestamp":1741220959,"startTime":"0","endTime":"0","summary":"【基石药业：在澳大利亚递交CS5001联合标准治疗用于一线DLBCL的临床试验申请】基石药业在港交所公告，公司管线2.0重磅产品CS5001（ROR1 ADC）联合标准治疗用于一线弥漫大B细胞淋巴瘤（DLBCL）的Ib期临床试验申请已在澳大利亚递交。此外，CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202503063337834050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","BK1141","03347","BK1583"],"gpt_icon":0},{"id":"2517979350","title":"【中信建投：AI制药潜力释放，有望重塑医药未来图景】中信建投研报表示，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。目前AI算法在临床前药物发现阶段已经有着深入且深刻的应用，海外头部临床CRO公司在临床试验中已经布局AI多年，完全由AI研发的新药有望在1-2年内成功上市。AI有望重塑药物发现的模式，并且为制药行业带来潜移默化且持续地降本增效，驱动AI制药管线和市场的快速增长，看好AI制药行业长期的发展潜力及前景。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517979350","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517979350?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 08:24","pubTimestamp":1741220695,"startTime":"0","endTime":"0","summary":"中信建投研报表示，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。目前AI算法在临床前药物发现阶段已经有着深入且深刻的应用，海外头部临床CRO公司在临床试验中已经布局AI多年，完全由AI研发的新药有望在1-2年内成功上市。AI有望重塑药物发现的模式，并且为制药行业带来潜移默化且持续地降本增效，驱动AI制药管线和市场的快速增长，看好AI制药行业长期的发展潜力及前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06082448553034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","01477","09939","BK1583","BK0276","BK1161","BK1515","159938","BK1191","BK1141","BK1574","BK1576","601066"],"gpt_icon":0},{"id":"2517976961","title":"中信建投：AI制药潜力释放，有望重塑医药未来图景","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976961","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517976961?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 08:16","pubTimestamp":1741220177,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1574","BK0276","BK1141","159938","03347","BK1583","BK1161","BK1576","601066","09939","BK1191","01477","BK1515"],"gpt_icon":0},{"id":"2517497936","title":"【基石药业-B(02616.HK)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请】基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517497936","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517497936?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 08:13","pubTimestamp":1741220034,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06081348552983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","ADC","BK1161","03347","BK4080","BK1141","02616","BK1583","BK4023","BK4231","BK1576","LU1169590202.USD","PD","LU1169589451.USD"],"gpt_icon":0},{"id":"2517763909","title":"基石药业-B(02616)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2517763909","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517763909?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 08:07","pubTimestamp":1741219667,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司已在澳大利亚成功递交CS5001联合标准治疗用于一线弥漫大B细胞淋巴瘤的Ib期临床试验申请。CS5001用于治疗多种实体瘤的全球多中心Ib期临床试验正在同步开展中。本次Ib期临床试验在CS5001单药治疗后线侵袭性和惰性晚期淋巴瘤的数据基础上进一步拓展，旨在深入探索ROR1 ADC在DLBCL全病程的临床应用价值，并持续拓展实体瘤治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","03347","BK1141","BK1574","BK1576","BK1583","BK4080","BK4231","ADC","BK1161"],"gpt_icon":0},{"id":"2517786999","title":"【宜明昂科-B(01541.HK)获国家药监局批准进行替达派西普联合珀维拉芙普α另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验】宜明昂科-B(01541.HK)发布公告，集团已获中华人民共和国国家药品监督管理局(国家药监局)批准进行IMM01(替达派西普)联合IMM2510(珀维拉芙普α)，另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验。这一重大进展标志着公司在快速推进IMM01(替达派西普)及IMM2510(珀维拉芙普α)的临床研究方面又迈出了关键一步。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517786999","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517786999?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 06:55","pubTimestamp":1741215326,"startTime":"0","endTime":"0","summary":"宜明昂科-B(01541.HK)发布公告，集团已获中华人民共和国国家药品监督管理局(国家药监局)批准进行IMM01(替达派西普)联合IMM2510(珀维拉芙普α)，另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验。这一重大进展标志着公司在快速推进IMM01(替达派西普)及IMM2510(珀维拉芙普α)的临床研究方面又迈出了关键一步。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06065548551590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK1161","03347","01541","BK1583","BK1576"],"gpt_icon":0},{"id":"2517392070","title":"宜明昂科-B(01541)获国家药监局批准进行替达派西普联合珀维拉芙普α另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2517392070","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517392070?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 06:45","pubTimestamp":1741214752,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，集团已获中华人民共和国国家药品监督管理局批准进行IMM01联合IMM2510，另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验。这一重大进展标志着公司在快速推进IMM01及IMM2510的临床研究方面又迈出了关键一步。凭借差异化的分子设计，IMM01表现出良好的安全性并证实其激活巨噬细胞的能力。集团拥有IMM01的全球知识产权及商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK1576","01541","BK1141","03347"],"gpt_icon":0},{"id":"2517111989","title":"第一三共/阿斯利康(AZN.US)重磅抗体偶联药物(ADC)Enhertu在3期临床试验中获得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2517111989","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517111989?lang=zh_cn&edition=fundamental","pubTime":"2025-03-05 21:15","pubTimestamp":1741180517,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿斯利康和第一三共公司日前宣布，双方联合开发的重磅抗体偶联药物Enhertu，在3期临床试验DESTINY-Gastric04中获得积极结果。新闻稿表示，Enhertu是首个在随机3期临床试验中，作为二线疗法显著改善HER2阳性胃癌患者总生存期的HER2靶向疗法。新闻稿指出，转移性HER2阳性胃癌一线治疗出现疾病进展后，历史上在随机临床试验中，尚未有HER2靶向药物在二线治疗中展示出生存获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765992.SGD","LU2456880835.USD","BK1576","BK4231","LU0109394709.USD","LU1829250122.USD","LU2417539215.USD","BK4588","ADC","BK4080","LU2462157665.USD","BK1583","BK1141","AZN","BK4568","BK4007","LU2236285917.USD","03347","LU0889565916.HKD","BK4585"],"gpt_icon":0}],"pageSize":16,"totalPage":14,"pageCount":2,"totalSize":217}]}}